MX2017014714A - Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4). - Google Patents

Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4).

Info

Publication number
MX2017014714A
MX2017014714A MX2017014714A MX2017014714A MX2017014714A MX 2017014714 A MX2017014714 A MX 2017014714A MX 2017014714 A MX2017014714 A MX 2017014714A MX 2017014714 A MX2017014714 A MX 2017014714A MX 2017014714 A MX2017014714 A MX 2017014714A
Authority
MX
Mexico
Prior art keywords
pad4 inhibitors
benzoimidazole derivatives
pad4
inhibitors
benzoimidazole
Prior art date
Application number
MX2017014714A
Other languages
English (en)
Inventor
Amans Dominique
John Atkinson Stephen
David Barker Michael
Campbell Matthew
Diallo Hawa
Douault Clement
Stuart Garton Neil
Liddle John
Fanny Renaux Jessica
John Sheppard Robert
Louise Walker Ann
Roland Wellaway Christopher
Matthew Wilson David
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MX2017014714A publication Critical patent/MX2017014714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Materials For Medical Uses (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)

Abstract

Compuestos de la Fórmula (I): (ver Fórmula) en donde X, Y, R1 y R3-R11 son como se definen en la presente, y sus sales son inhibidores de PAD4 y pueden ser útiles en el tratamiento de diversos trastornos, por ejemplo, artritis reumatoide, vasculitis, lupus eritematoso sistémico, colitis ulcerosa, cáncer, fibrosis quística, asma, lupus eritematoso cutáneo y psoriasis.
MX2017014714A 2015-05-21 2016-05-19 Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4). MX2017014714A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164906P 2015-05-21 2015-05-21
PCT/IB2016/000761 WO2016185279A1 (en) 2015-05-21 2016-05-19 Benzoimidazole derivatives as pad4 inhibitors

Publications (1)

Publication Number Publication Date
MX2017014714A true MX2017014714A (es) 2018-01-25

Family

ID=56235853

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014714A MX2017014714A (es) 2015-05-21 2016-05-19 Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4).

Country Status (15)

Country Link
US (2) US10407407B2 (es)
EP (1) EP3298003B1 (es)
JP (1) JP6703553B2 (es)
KR (1) KR20180005250A (es)
CN (1) CN107849015B (es)
AR (1) AR106863A1 (es)
AU (1) AU2016264958B2 (es)
BR (1) BR112017024678A2 (es)
CA (2) CA3199601A1 (es)
EA (1) EA033680B1 (es)
ES (1) ES2945314T3 (es)
IL (2) IL255666A (es)
MX (1) MX2017014714A (es)
TW (1) TW201706263A (es)
WO (1) WO2016185279A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4
CN109071497B (zh) 2016-02-23 2021-10-22 帕德罗科治疗公司 Pad4杂芳基抑制剂
JP6987843B2 (ja) * 2016-07-27 2022-01-05 パドロック・セラピューティクス・インコーポレイテッドPadlock Therapeutics, Inc. Ｐａｄ４の共有結合性阻害剤
CN110248934B (zh) 2016-09-12 2022-05-24 帕德罗科治疗公司 杂芳基pad4抑制剂
RU2764243C2 (ru) * 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
PT3697785T (pt) * 2017-10-18 2023-04-03 Jubilant Epipad LLC Compostos de imidazopiridina como inibidores de pad
KR20200085836A (ko) 2017-11-06 2020-07-15 주빌런트 프로델 엘엘씨 Pd1/pd-l1 활성화 억제제로서의 피리미딘 유도체
PT3704120T (pt) 2017-11-24 2024-07-03 Jubilant Episcribe Llc Compostos heterocíclicos como inibidores de prmt5
TW201938164A (zh) 2018-01-08 2019-10-01 瑞士商赫孚孟拉羅股份公司 新穎雜環化合物
EP3746430A4 (en) * 2018-02-02 2021-11-03 Padforward LLC INHIBITORS OF PROTEIN ARGININE DEIMINASES
BR112020018610A2 (pt) 2018-03-13 2020-12-29 Jubilant Prodel LLC Compostos de fórmula i, fórmula ii, fórmula iii, fórmula iv, fórmula v, fórmula vi, ou seus polimorfos, estereoisômeros, tautômeros, profármacos, solvatos e sais farmaceuticamente aceitáveis dos mesmos e uso dos mesmos; processo de preparação; composição farmacêutica; e método para o tratamento e/ou prevenção de várias doenças, que incluem câncer e doenças infecciosas
SG11202007608UA (en) 2018-03-22 2020-09-29 Hoffmann La Roche Oxazine monoacylglycerol lipase (magl) inhibitors
US20220402950A1 (en) * 2018-08-08 2022-12-22 Bristol-Myers Squibb Company Substituted benzimidazoles as pad4 inhibitors
US11981680B2 (en) 2018-08-08 2024-05-14 Bristol-Myers Squibb Company Substituted thienopyrroles as PAD4 inhibitors
WO2020033520A1 (en) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Indole and azaindole inhibitors of pad enzymes
CN112789087B (zh) * 2018-08-08 2024-08-13 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
MA53220A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de monoacylglycérol lipase
RU2769507C1 (ru) 2018-08-13 2022-04-01 Ф. Хоффманн-Ля Рош Аг Новые гетероциклические соединения как ингибиторы моноацилглицеринлипазы
SI3883936T1 (sl) 2018-11-22 2023-10-30 F. Hoffmann - La Roche Ag Nove heterociklične spojine
US20210094971A1 (en) 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
KR20220062515A (ko) 2019-09-12 2022-05-17 에프. 호프만-라 로슈 아게 Magl 억제제로서 4,4a,5,7,8,8a-헥사피리도[4,3-b][1,4]옥사진-3-온 화합물
PE20221340A1 (es) 2019-09-24 2022-09-13 Hoffmann La Roche Compuestos heterociclicos
EP4034602A1 (en) 2019-09-24 2022-08-03 F. Hoffmann-La Roche AG Fluorescent probes for monoacylglycerol lipase (magl)
KR20220069003A (ko) 2019-09-24 2022-05-26 에프. 호프만-라 로슈 아게 헤테로사이클릭 모노아실글리세롤 리파제(magl) 억제제
CN112574230B (zh) * 2019-09-27 2022-10-28 药捷安康(南京)科技股份有限公司 肽酰精氨酸脱亚胺酶抑制剂及其用途
JP2023512557A (ja) * 2020-02-06 2023-03-27 ブリストル－マイヤーズ スクイブ カンパニー 免疫抑制剤として有用な大環状ｐａｄ４阻害剤
TW202140477A (zh) * 2020-02-12 2021-11-01 美商必治妥美雅史谷比公司 雜環ｐａｄ４抑制劑
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
WO2021222353A1 (en) * 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
JP2023538018A (ja) * 2020-08-12 2023-09-06 ジュビラント・エピパッド・エルエルシー ネトーシスの処置及び／又は予防における使用のための方法及び化合物
WO2022049134A1 (en) 2020-09-03 2022-03-10 F. Hoffmann-La Roche Ag Heterocyclic compounds
US11878965B2 (en) 2020-12-22 2024-01-23 Gilead Sciences, Inc. Inhibitors of peptidylarginine deiminases
EP4433477A1 (en) * 2021-11-15 2024-09-25 Regor Pharmaceuticals, Inc. Pad4 inhibitors and use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU570439B2 (en) 1983-03-28 1988-03-17 Compression Labs, Inc. A combined intraframe and interframe transform coding system
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
TR199701167T1 (xx) 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Albuterol i�in �l��lm�� doz inhaleri.
TW533865U (en) 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
US6315112B1 (en) 1998-12-18 2001-11-13 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2002334217B2 (en) * 2001-10-26 2008-07-03 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
BRPI0416128B8 (pt) 2003-11-03 2021-06-22 Glaxo Group Ltd dispositivo de dispensação de fluido
US7429611B2 (en) * 2004-09-23 2008-09-30 Bristol-Myers Squibb Company Indole inhibitors of 15-lipoxygenase
UY32138A (es) 2008-09-25 2010-04-30 Boehringer Ingelheim Int Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
SG10201401169QA (en) * 2009-04-02 2014-05-29 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
CA2785037C (en) * 2009-12-21 2018-01-16 Samumed, Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
KR101916443B1 (ko) * 2012-07-26 2018-11-08 글락소 그룹 리미티드 Pad4 억제제로서의 2-(아자인돌-2-일) 벤즈이미다졸
AR107032A1 (es) * 2015-12-09 2018-03-14 Padlock Therapeutics Inc Inhibidores bicíclicos de pad4

Also Published As

Publication number Publication date
JP6703553B2 (ja) 2020-06-03
BR112017024678A2 (pt) 2018-07-31
AU2016264958A1 (en) 2017-12-07
ES2945314T3 (es) 2023-06-30
KR20180005250A (ko) 2018-01-15
WO2016185279A1 (en) 2016-11-24
EA201792517A1 (ru) 2018-04-30
AU2016264958B2 (en) 2020-10-29
US10815218B2 (en) 2020-10-27
EP3298003A1 (en) 2018-03-28
CA2986199A1 (en) 2016-11-24
AR106863A1 (es) 2018-02-28
US20200095227A1 (en) 2020-03-26
IL278916A (en) 2021-01-31
EA033680B1 (ru) 2019-11-15
CA2986199C (en) 2023-07-18
EP3298003B1 (en) 2023-04-19
IL255666A (en) 2018-01-31
JP2018520105A (ja) 2018-07-26
US20180297983A1 (en) 2018-10-18
CN107849015A (zh) 2018-03-27
US10407407B2 (en) 2019-09-10
CN107849015B (zh) 2021-03-19
CA3199601A1 (en) 2016-11-24
TW201706263A (zh) 2017-02-16

Similar Documents

Publication Publication Date Title
MX2017014714A (es) Derivados de benzoimidazol como inhibidores de peptidil arginina deiminasa 4 (pad4).
IN2014KN02935A (es)
ZA201807736B (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
CY1121831T1 (el) Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk
TN2017000544A1 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
EP3500677A4 (en) UNIQUE GUIDE RNA, CRISPR / CAS9 SYSTEMS AND METHODS OF USE
ZA201706918B (en) Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof
MX2020011558A (es) Imidazolonilquinolinas y el uso de las mismas como inhibidores de cinasa atm.
EP3041948A4 (en) Alternative nucleic acid molecules containing reduced uracil content and uses thereof
PH12016502099A1 (en) 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
PH12016501567A1 (en) 4`-difluoromethyl substituted nucleoside derivatives as inhibitors of influenza rna replication
PH12016500270A1 (en) Combination of a mek inhibitor and an erk inhibitor for use in treatment of hyperproliferative diseases
EP3509591A4 (en) NOVEL SELECTIVE INHIBITORS OF JAK1 AND USES THEREOF
MX2017013880A (es) Derivados del acido tetrahidronaftiridinil propionico y usos de los mismos.
EA201300283A1 (ru) Производные фуропиридина
MX2018001576A (es) Piridinas y su uso en el tratamiento del cancer.
SG10201601801PA (en) Sense amplifier and latching scheme
SI3196194T1 (sl) Pirimidinski derivati, uporabni kot selektivni inhibitorji JAK3 in/ali JAK1
IL268880A (en) Foliar feeding formulations and methods of using them
EP3245204A4 (en) Small molecules for the treatment of primary cancer and cancer metastasis
EP3628374A3 (en) Bcl-3 inhibitors
IL255290A0 (en) Substances that bind to egf1 and their use in the treatment of inflammatory diseases and tumors
PH12018501213A1 (en) 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1h-pyrazol-3-ylamino)pyrazine-2-carbonitrile (s)-lactate monohydrate
EP3719172A4 (en) REACTOR FOR GENERATING HYDROGEN BY REDUCING HYDRONIUM IONS IN THE CHEMICAL EQUILIBRIUM IN WATER AND BY OXIDATION OF THE ORGANIC MOLECULES EMBEDDED IN THE EXCLUSION